The four day conference beginning on Saturday 19 October is expected to draw approximately 3000 academics, scientists and pharmaceutical industry representatives from all over the world. The conference will focus on innovations in drug development, target selection and the impact of new discoveries in molecular biology.
The first poster, Therapeutic targeting of colorectal cancer stem cells with BNC101, a functional anti-LGR5 monoclonal antibody, will be presented as part of a cancer stem cells (CSCs) session on Sunday 20 October.
It will show preclinical data supporting Bionomics' therapeutic strategy for treating cancer by the targeting of CSCs with BNC101, prolonging patient survival by preventing CSCs from re-seeding cancer following frontline surgery and standard of care chemotherapy.
BNC101 is an LGR5 targeting monoclonal antibody (mAb) currently undergoing pre-clinical IND-enabling studies for scheduled Phase I clinical studies in 2014. LGR5 is a validated CSC receptor over expressed in colorectal cancer, pancreatic, breast and most other solid tumours.
The BNC105 presentation, Induction of tumour hypoxia synergises with inhibitors of tumour metabolic and angiogenic adaptive responses to suppress tumour growth and enhance host survival, will highlight data that further expands and consolidates the therapeutic utility of BNC105 in renal cancer. The poster is part of a session on cellular responses on Monday 21 October.
Using animal models of kidney cancer Bionomics has demonstrated BNC105 combines effectively with therapies that are the current standard of care in the first and second lines of treatment for patients with metastatic renal cancer.
Votrient® (GSK) and Afinitor® (Novartis) are the drugs used as first and second line therapies respectively. Both combine safely with BNC105 and show improved therapeutic benefit compared to their use in isolation.
In June Bionomics reported the completion of enrolment into a Phase II trial of BNC105 in patients with metastatic renal cancer. Top line results of this trial are anticipated in early 2014.
The AACR is the world's largest and oldest scientific organisation focused on all aspects of high quality and innovative cancer research. It was founded in 1907 by a group of 11 physicians and scientists interested in cancer research. It accelerates progress toward the prevention and cure of cancer by promoting education, communication, research and collaboration.
Most Popular Stories
- 15 Myths That Could Ruin Your Hispanic Ad Campaign
- Bitcoin Clones Lurch Onto Financial Scene
- General Motors Names Mary Barra as First Female CEO
- Clinton to Keynote Annual Simmons Leadership Conference
- AIG to Create 230 Jobs in Charlotte
- How Bitcoin and Other Cryptocurrencies Work
- Californians Want to Legalize Marijuana
- Selena Gomez, Shakira Among Top Hispanic Searches
- Pacific Trade Pact Delay Hinders U.S. Pivot to Asia
- PhD Project Grooms Business Profs